Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GSK. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

  • Q4 2022 Income statement and product revenue figures are as at 25/01/2023
  • FY 2022-2026 Income statement and product revenue figures are as at 25/01/2023
Income Statement

 

£m (unless stated) Q422 Q422 n= 2022 2023 2024 2025 2026 2022-2026 n=
Turnover - Specialty ex pandemic solutions 2,423 15 8,827 9,798 10,749 11,554 12,213 15
Turnover - General Medicines 2,581 15 10,078 10,032 9,948 9,871 9,802 15
Turnover - Vaccines ex pandemic solutions 2,012 15 7,869 8,977 9,993 10,906 11,686 15
Turnover - GSK excluding pandemic solutions 7,016 15 26,774 28,808 30,691 32,331 33,701 15
Turnover - pandemic solutions 55 15 2,245 59 27 21 18 15
Turnover - GSK 7,071 15 29,019 28,867 30,717 32,351 33,719 15
Cost of sales (2,057) 15 (8,768) (7,666) (8,059) (8,410) (8,705) 15
Selling, general and administration (2,226) 15 (7,919) (8,289) (8,600) (8,829) (9,046) 15
Research and Development (1,510) 15 (5,050) (5,274) (5,514) (5,740) (5,937) 15
Royalty income 209 15 761 886 485 536 569 15
Operating profit 1,487 15 8,043 8,524 9,029 9,908 10,600 15
Net finance costs (220) 15 (776) (676) (621) (580) (544) 15
Associates - 15 (4) (1) (1) (1) (1) 15
Profit before tax 1,267 15 7,263 7,846 8,407 9,327 10,055 15
Taxation (255) 15 (1,221) (1,266) (1,356) (1,507) (1,628) 15
Tax Rate 20.1% 15 16.8% 16.1% 16.1% 16.2% 16.2% 15
Profit after tax  1,012 15 6,041 6,580 7,050 7,820 8,427 15
Minority interests (159) 15 (605) (655) (697) (732) (755) 15
Profit attributable to shareholders 853 15 5,437 5,925 6,354 7,087 7,672 15
WANS (m) 4,030 15 4,024 4,041 4,059 4,073 4,085 15
Earnings per share (p) 21.2 15 135.1 146.6 156.5 174.0 187.8 15
Dividend per share (p) 11.8 13 59.3 56.4 59.2 62.1 64.7 13
Free Cash Flow n/a n/a 3,206 4,687 5,329 6,108 6,589 11
Net Debt n/a n/a (14,731) (12,419) (9,515) (6,086) (2,361) 12
                 
USD / GBP 1.19 15 1.24 1.21 1.21 1.21 1.21 15
EUR / GBP 1.15 14 1.17 1.14 1.14 1.14 1.14 14
JPY / GBP 166 11 162 159 161 161 161 11

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research

Specialty medicines

 

Turnover £m Q422 Q422 n= 2022 2023 2024 2025 2026 2022-2026 n=
                 
Tivicay 333 14 1,341 1,216 1,097 998 904 14
Triumeq 447 14 1,767 1,546 1,343 1,162 1,000 14
Juluca 170 15 614 664 689 704 712 15
Dovato 398 15 1,335 1,760 2,052 2,262 2,411 15
Dolutegravir based regimens 1,348 15 5,057 5,186 5,181 5,126 5,027 15
Cabenuva 123 15 334 633 903 1,155 1,362 15
Apretude 19 15 39 154 303 459 588 15
Cabotegravir +/- rilpivirine 142 15 373 787 1,206 1,614 1,951 15
Rukobia 26 15 82 120 149 170 186 15
Other HIV 27 n/a 102 86 78 79 91 n/a
HIV 1,543 15 5,614 6,178 6,614 6,989 7,255 15
                 
Benlysta 321 15 1,141 1,304 1,415 1,434 1,400 15
Nucala 393 15 1,421 1,596 1,708 1,779 1,807 15
                 
Zejula 124 15 462 495 557 618 680 15
Blenrep 31 15 122 64 88 109 129 15
Jemperli 10 15 26 61 97 134 164 15
                 
momelotinib - 15 - 29 103 191 280 15
daprodustat - 14 - 38 107 168 223 14
                 
Specialty Medicines ex pandemic solutions 2,423 15 8,827 9,798 10,749 11,554 12,213 15
                 
Xevudy 50 15 2,234 54 21 14 11 15
                 
Specialty Medicines 2,473 15 11,061 9,853 10,770 11,568 12,224 15

 

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research

Vaccines

 

Turnover £m Q422 Q422 n= 2022 2023 2024 2025 2026 2022-2026 n=
Bexsero 150 15 753 814 837 853 865 15
Menveo 56 15 324 343 345 344 344 15
Other Meningitis 13 9 30 32 32 32 32 9
Meningitis 219 15 1,107 1,189 1,214 1,229 1,241 15
Fluarix/Flulaval 266 15 704 726 742 759 775 15
Shingrix 748 15 2,937 3,659 4,243 4,648 4,889 15
Boostrix 135 15 598 623 634 644 654 15
Cervarix 26 14 117 117 116 115 114 14
Hepatitis 135 15 580 642 668 687 700 15
Infanrix, Pediarix 130 15 613 617 615 614 614 15
Rotarix 163 15 543 560 569 577 585 15
Synflorix 89 15 326 318 307 297 290 15
Established Vaccines 779 15 3,121 3,219 3,253 3,279 3,298 15
RSV OA - 15 - 169 480 848 1,219 15
Vaccines ex pandemic solutions 2,012 15 7,869 8,977 9,993 10,906 11,686 15
Pandemic solutions 5 15 11 5 5 6 7 15
Vaccines 2,017 15 7,880 8,982 9,998 10,912 11,693 15

 

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research

General medicines

 

Turnover £m Q422 Q422 n= 2022 2023 2024 2025 2026 2022-2026 n=
Anoro 124 15 469 475 491 493 495 15
Arnuity 15 15 60 62 63 64 65 15
Avamys/Veramyst 70 14 309 284 259 243 229 14
Flixotide/Flovent 115 15 526 484 456 432 409 15
Incruse 55 15 212 216 219 221 223 15
Relvar/Breo 294 15 1,190 1,181 1,163 1,143 1,122 15
Seretide/Advair 274 15 1,103 975 876 797 731 15
Trelegy 496 15 1,768 2,154 2,417 2,617 2,787 15
Ventolin 182 15 747 704 669 639 613 15
Respiratory 1,654 15 6,520 6,663 6,732 6,759 6,779 15
Other General Medicines 927 15 3,558 3,369 3,216 3,111 3,023 15
                 
General Medicines 2,581 15 10,078 10,032 9,948 9,871 9,802 15

 

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research

Back to top